Leinco Technologies

Recombinant Human IL-12

Product Code:
 
LEI-I-214
Product Group:
 
Recombinant Proteins
Host Type:
 
Human
Regulatory Status:
 
RUO
Shipping:
 
Ambient
Storage:
 
This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-I-214-25ug25 ug£1,024.00
Quantity:
LEI-I-214-5ug5 ug£1,558.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Long Description:
IL-12 plays a role in resistance against pathogens via the differentiation of naive T cells into Th1 cells. It stimulates the growth and function of T cells, blocks formation of new blood vessels, and contributes to antimycobacterial immune response. In addition, it promotes the production of IFN-γ and TNF-α and reduces IL-4 mediated suppression of IFN-γ. Consequently, this enhances the immunostimulatory and immunomodulatory effects of IFN-γ. In addition, there appears to be a link between IL-2 and the signal transduction of IL-12 in NK cells, which enhances the functional response of IL-12 via IFN-γ production and killing of target cells. Furthermore, IL-12 is thought to be associated with autoimmunity. IL-12 was shown to worsen the condition when administered to people already suffering from autoimmune diseases. Comparatively, inhibition of IL-12 (either through IL-12 gene knock-out in mice or treatment of mice with IL-12 mAbs) improved the disease.
Purity:
>97% by SDS-PAGE and analyzed by silver stain.
Target:
IL-12

References

1. Kapsenberg, ML. et al. (1997) J. Immunol. 159: 28 2. Ritz, J. et al. (2001) Blood. 97(12):3860-6.3. Barnes, PF. et al. (1994) J Clin Invest. 93(4):1733-9.